BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

New Virttu Biologics Replicate Open Innovation Forum Provides Unique R&D Network for New Oncology Combination Therapies


11/5/2012 12:10:50 PM

Glasgow, November 5th, 2012: Virttu Biologics Limited, a UK biotechnology company with expertise in the field of oncolytic viruses, has announced the launch of the Virttu REPLICATE™ Open Innovation Forum. Accessible to researchers in institutes and biotechnology and pharmaceutical companies, the REPLICATE Open Innovation Forum aims to stimulate development of new oncology combination therapies by providing access to Virttu’s oncolytic virus, SEPREHVIR™ (HSV1716).

According to Virttu CEOSteven Powell, there are many benefits to potential partners in joining Virttu REPLICATE Open Innovation Forum: “In recent years we have been approached regularly by research groups interested in investigating the use of SEPREHVIR™ in oncology indications, either as a monotherapy or in combination with other treatment modalities. With interest in oncolytic viruses continuing to grow, establishing a formal collaborative network seemed the most efficient way forward. By joining Virttu REPLICATE, researchers gain access to latest data and insights into the use of oncoviruses and access to SEPREHVIR™ – an engineered herpes simplex virus which is highly lytic, has a broad tissue tropism, replicatesselectively in cancer cells and with safety demonstrated in man. In due course we believe this new and innovative initiative will lead to exciting opportunities to create breakthrough research and combination therapies with real clinical impact. “

www.virttureplicate.co.uk

info@virttureplicate.co.uk

Follow us on Twitter @virttureplicate

Media and Press Enquiries:

Richard Hayhurst Associates

Richard Hayhurst Tel : +44(0) 20 3077 5400



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES